Loading…
ARKA Clinical Decision Support is designed to meet all four criteria for Non-Device CDS under FD&C Act §520(o)(1)(E) and FDA's January 2026 final guidance on Clinical Decision Support Software. Recommendations support, not replace, the clinician's judgment. Every recommendation is anchored in a published guideline or peer-reviewed source, with the basis available for independent review. CLIN emphasizes imaging appropriateness at order entry.
This recommendation is intended to support, not replace, clinical judgment. It is generated by ARKA, software designed to meet the four criteria for Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E) and FDA's final guidance on Clinical Decision Support Software (January 2026). The clinician is responsible for the final decision.
For the CFO
You own net revenue on a service line that is at once your highest-margin and your most-denied. In 2024 initial claim denials rose ~2.4% to ~11.8% and kept climbing, ~65% of denied claims are never reworked, and collections on insured balances fell to ~34%. Advanced imaging concentrates that leakage — and it is preventable at the point of order.
Your scorecard
The KPIs your board and leadership team track — where imaging leakage shows up first.
The problem
Benchmark-backed pain points tied to the metrics you own.
~65% of denials never reworked
The scan was delivered; the margin is gone because the denial was never reworked.
$25–$118 / claim
Every denied claim costs ~$25–$118 to rework; appeals exceed $100 — and most are never filed.
20–40% advanced-imaging PA
Initial denial rates climbed to ~11.8% in 2024; advanced-imaging prior auth runs far higher.
The fix
Each lever maps to a pain above — same order, same grid, so the pairing is obvious.
ARKA documents medical necessity at the point of order, so clean claims go out first time — it sits UPSTREAM of your RCM vendor.
Modeled ~$3.5M/yr recovered for a regional group, with payback under 6 months.
PMPM/per-order pricing, zero upfront capital, and a pilot success-threshold guarantee (month 1 of production free if it misses).
The numbers
Modeled or published figures — labeled with their basis.
~$3.5M
modeled annual recovery
120k advanced studies, conservative
~2.3–2.9×
modeled first-year ROI
gross benefit ÷ ARKA Pro PMPM
<6 mo
modeled payback
see the ROI calculator
Evidence
What we bring to the conversation — sourced from the ARKA buyer playbook.
Pushback
The concerns we hear most — and how we address them.
ARKA prevents denials at the point of order — upstream of RCM, not competing with it. Your RCM team works the denials that still happen; ARKA shrinks how many happen.
There isn't one — it's OpEx (PMPM/per-order), and the pilot is risk-free: miss the agreed threshold and month one of production is free.
The ROI model runs on your volume and payer mix, and the pilot reports denial-rate reduction, time-to-auth, and documentation completeness against your own 90-day baseline.
Your agenda
Three questions to put on the table — we'll answer with your data, not generic slides.
Question 1: What is your current advanced-imaging denial rate and annual write-off $?
Question 2: What does it cost you to rework one denied claim?
Question 3: What share of denials are never reworked?
Explore
Jump into the modules most relevant to your seat.
20-minute CFO briefing with a pre-built ROI model customized to your volume and payer mix.
Quick answers
Modeled under six months for a mid-sized system — the calculator shows it for your numbers.
Figures are modeled on published CAQH/MGMA/KFF/AMA sources and labeled as such; pilots report measured results against your baseline.
20-minute CFO briefing with a pre-built ROI model customized to your volume and payer mix.
